Financial & Tax Architects LLC purchased a new position in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 6,963 shares of the company’s stock, valued at approximately $481,000.
Other large investors also recently made changes to their positions in the company. Parkside Financial Bank & Trust raised its stake in AstraZeneca by 4,875.0% during the 1st quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock valued at $26,000 after purchasing an additional 390 shares during the last quarter. Fairfield Bush & CO. bought a new stake in shares of AstraZeneca in the 1st quarter valued at about $28,000. Accurate Wealth Management LLC acquired a new position in AstraZeneca in the fourth quarter valued at about $30,000. Red Tortoise LLC acquired a new position in AstraZeneca in the fourth quarter valued at about $30,000. Finally, Financial Management Professionals Inc. lifted its position in AstraZeneca by 68.6% in the 4th quarter. Financial Management Professionals Inc. now owns 467 shares of the company’s stock valued at $32,000 after acquiring an additional 190 shares in the last quarter. Institutional investors own 16.42% of the company’s stock.
AstraZeneca Price Performance
Shares of AstraZeneca stock traded down $0.45 on Thursday, reaching $74.42. 568,613 shares of the stock were exchanged, compared to its average volume of 4,763,004. The firm’s 50 day moving average is $70.55 and its 200-day moving average is $68.32. AstraZeneca PLC has a one year low of $52.65 and a one year high of $76.56. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.70 and a current ratio of 0.90. The firm has a market cap of $230.68 billion, a PE ratio of 49.26, a P/E/G ratio of 1.52 and a beta of 0.52.
AstraZeneca (NASDAQ:AZN – Get Rating) last issued its quarterly earnings results on Thursday, February 9th. The company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.01. AstraZeneca had a net margin of 10.73% and a return on equity of 28.86%. The company had revenue of $11.21 billion during the quarter, compared to the consensus estimate of $11.40 billion. As a group, analysts anticipate that AstraZeneca PLC will post 3.67 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
AZN has been the topic of a number of recent research reports. Morgan Stanley upgraded shares of AstraZeneca from an “equal weight” rating to an “overweight” rating in a report on Tuesday, April 11th. Berenberg Bank upped their price objective on AstraZeneca from GBX 118 ($1.49) to GBX 126 ($1.59) in a report on Wednesday, January 18th. Finally, StockNews.com started coverage on AstraZeneca in a research report on Thursday, March 16th. They set a “strong-buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, AstraZeneca currently has a consensus rating of “Moderate Buy” and an average target price of $126.00.
About AstraZeneca
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider AstraZeneca, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and AstraZeneca wasn’t on the list.
While AstraZeneca currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
This post was originally published on this site be sure to check out more of their content.
